Suchergebnisse - "Mata Marín, José Antonio"

PubPharm (56)

1

Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment : A real-world prospective study

enthalten in: International journal of STD & AIDS | 2024

von Mata Marín, J. | Velasco-Penagos, J. | Mauss, S. | +5

2

Risk factors for mortality and clinical presentation of monkeypox

enthalten in: AIDS (London, England) | 2023

von Triana-González, S. | Román-López, C. | Mauss, S. | +5

3

Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients

enthalten in: AIDS research and human retroviruses | 2023

von Pérez-Barragán, E. | Guevara-Maldonado, M. | Mancilla-Galindo, J. | +4

4

Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19

enthalten in: Microbiology spectrum | 2023

von Qiu, J. | Engelbrektson, A. | Song, L. | +15

5

HIV viral load and CD4+ count are not associated with experiencing Covid-19 vaccine adverse events : case-control study

enthalten in: Salud publica de Mexico | 2023

von Pérez-Barragán, E. | Mata-Marín, J. | Mancilla-Galindo, J. | +2

6

COVID-19 in people living with HIV : a single-center descriptive study

enthalten in: Journal of infection in developing countries | 2022

von Pérez-Barragán, E. | Castillo-Flores, J. | Mata-Marín, J. | +3

7

Contribution of APOA5, APOC3, CETP, ABCA1 and SIK3 genetic variants to hypertriglyceridemia development in Mexican HIV-patients receiving antiretroviral therapy

enthalten in: Pharmacogenetics and genomics | 2022

von Bautista-Martínez, J. | Mata-Marín, J. | Sandoval-Ramírez, J. | +22

8

Risk factors for HCV transmission in HIV-positive men who have sex with men in México

enthalten in: PloS one | 2022

von Mata-Marín, J. | de Pablos-Leal, A. | Mauss, S. | +7

9

A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress

enthalten in: Archives of virology | 2020

von Cázares-Cortazar, A. | Uribe-Noguez, L. | Mata-Marín, J. | +6

10

A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress

enthalten in: Archives of virology | 2020

von Cázares-Cortazar, A. | Uribe-Noguez, L. | Mata-Marín, J. | +6

1
2
3
4
5
6
Nächster »
[6]